N. Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem. Soc. Trans. 44, 377–385 (2016). CAS Google Scholar D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L. & Alimandi, M. CAR-T cells: the long and winding road...
et al. A homing system targets therapeutic T cells to brain cancer. Nature 561, 331 (2018). Article ADS CAS PubMed PubMed Central Google Scholar Peters, B., Nielsen, M. & Sette, A. T cell epitope predictions. Annu. Rev. Immunol. 38, 123 (2020). Article CAS PubMed PubMed ...
Various chemokines including CCL21 and CXCL12 are involved in B cell migration, but they are not CLL-specific and are thus not ideal therapeutic targets15,18. ROR1 is another CLL-specific receptor that promotes CLL cell migration via Wnt5a signaling and has been validated as a therapeutic ...
Extensive research on the CXCL12-CXCR4 axis in acute myeloid leukemia (AML) has resulted in the incorporation of novel anti-leukemia drugs targeting this axis into therapeutic strategies. However, despite this progress, a comprehensive and up-to-date review addressing the role of the CXCL12-CXCR4...
Red blood cells (RBCs) are the most abundant cells in the body, possessing unique biological and physical properties. RBCs have demonstrated outstanding potential as delivery vehicles due to their low immunogenicity, long-circulating cycle, and immune ch
Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke. 157, 49-78 (2017). Google Scholar Campisi and d'Adda, 2007 Campisi, J. & d'Adda di Fagagna, F. Cellular senescence: when bad things happen to good cells. Nature Reviews Molecular Cell Biology 8, 729-740 ...
Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med. 2021;2(7):100346. Article CAS PubMed PubMed Central Google Scholar Imlach WL, Beck ES, Choi BJ, Lotti F, Pellizzoni L, McCabe BD. SMN is required for sensory-motor ...
AP2 targets the cytoplasmic tyrosine containing the YVKM motif of CTLA-4 and can be disengaged when this motif is tyrosine-phosphorylated upon T-cell activation.24,28 However, the immunological settings where the CTLA-4-AP-2 interaction is disrupted are unclear because activated T cells and ...
which severely limits the diffusion rates of formulated STING agonists into tumor stroma and undermines their potential immunotherapeutic efficacy. Taken together, these features highlight the necessity of rational STING agonist selection and strategic therapeutic design for effective cGAS-STING signaling in...
Cancer immunotherapies that target the immune checkpoints, such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD1 ligand-1 (PD-L1), have transformed the therapeutic landscape of a variety of malignancies1,2,3. However, despite compelling...